Recent Analysts’ Ratings Updates for PepGen (PEPG)

Several brokerages have updated their recommendations and price targets on shares of PepGen (NASDAQ: PEPG) in the last few weeks:

  • 5/31/2022 – PepGen is now covered by analysts at Wedbush. They set an “outperform” rating and a $17.00 price target on the stock.
  • 5/31/2022 – PepGen is now covered by analysts at SVB Leerink LLC. They set an “outperform” rating and a $40.00 price target on the stock.
  • 5/31/2022 – PepGen is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $24.00 price target on the stock.
  • 5/31/2022 – PepGen is now covered by analysts at Bank of America Co.. They set a “buy” rating and a $16.00 price target on the stock.

PEPG stock traded down $0.27 during trading on Wednesday, reaching $10.92. 82,277 shares of the stock were exchanged, compared to its average volume of 102,716. PepGen Inc. has a twelve month low of $7.82 and a twelve month high of $16.99.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen Inc is based in BOSTON.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for PepGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.